Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Corneal Disease: Clinical Insights and Management Approaches
share announcement

Corneal Disease: Clinical Insights and Management Approaches

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Ophthalmology".

Deadline for manuscript submissions: 28 April 2024 | Viewed by 1509

Special Issue Editor

Dr. Uri Elbaz

E-Mail Website
Guest Editor
1. Department of Ophthalmology, Rabin Medical Center, Schneider Children's Medical Center, Petach Tikva, Israel
2. Department of Ophthalmology, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Interests: corneal diseases; corneal transplantation; corneal dystrophies; dry eyes; blepharokeratoconjunctivitis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The Special Issue on "Corneal Disease: Clinical Insights and Management Approaches" aims to provide valuable research insights and address critical challenges in the diagnosis and treatment of corneal conditions. With a focus on clinical perspectives, this issue endeavors to bridge the gap between cutting-edge research and its practical implications in the field of ophthalmology.

The current research status underscores the significance of corneal diseases as a leading cause of visual impairment and blindness worldwide. Despite advancements in ocular research and medical technologies, the effective management of corneal diseases remains a complex task.

The scope of this Special Issue encompasses a wide range of topics, including, but not limited to:

  1. Novel diagnostic tools and imaging techniques for the early detection and precise assessment of corneal disorders;
  2. Evidence-based clinical strategies and management approaches for various corneal conditions, such as keratitis, corneal dystrophies, and corneal injuries;
  3. Advancements in corneal transplantation techniques and innovative therapies for corneal regeneration;
  4. Pharmacological interventions and surgical innovations to improve treatment outcomes;
  5. Patient-centered care and strategies to enhance the quality of life for individuals with corneal diseases.

The mobilization of this Special Issue calls upon researchers, ophthalmologists, and eye-care professionals to contribute original research articles, reviews, and case studies that shed light on the challenges and potential solutions in the clinical management of corneal diseases. By sharing clinical insights and evidence-based approaches, this Special Issue seeks to facilitate better clinical decision-making, improve treatment outcomes and ultimately contribute to preserving and restoring vision in patients with corneal disease.

Dr. Uri Elbaz
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • corneal diseases
  • keratoconus
  • keratitis
  • keratopathy
  • corneal dystrophies
  • dry eyes
  • blepharokeratoconjunctivitis

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 11294 KiB  
Article
Does Systemic Hematological Therapy Influence the Course of Paraproteinemic Keratopathy?
by Mohammad Al Hariri, Markus Munder, Norbert Pfeiffer and Joanna Wasielica-Poslednik
J. Clin. Med. 2024, 13(2), 565; https://doi.org/10.3390/jcm13020565 - 18 Jan 2024
Viewed by 572
Abstract
The purpose of this article is to evaluate the course of paraproteinemic keratopathy (PPK) in patients undergoing systemic therapy for the underlying hematological disease. Baseline and follow-up examinations included hematological work-up, best-corrected visual acuity, slit-lamp biomicroscopy, and in vivo confocal laser scanning microscopy [...] Read more.
The purpose of this article is to evaluate the course of paraproteinemic keratopathy (PPK) in patients undergoing systemic therapy for the underlying hematological disease. Baseline and follow-up examinations included hematological work-up, best-corrected visual acuity, slit-lamp biomicroscopy, and in vivo confocal laser scanning microscopy (IVCM). We included 22 patients with bilateral PPK (aged 68 ± 10.4 years, 11 males). Ten patients with multiple myeloma (MM) underwent on-label systemic therapy. During follow-up, we observed a regression of corneal opacities in three patients under slit-lamp examination and under IVCM, while PPK remained unchanged in seven patients. In three patients with monoclonal gammopathy of ocular significance (MGOS), systemic therapy was initiated off-label to reduce the serum paraprotein load before penetrating keratoplasty (PKP). These patients showed no signs of PPK recurrence for up to 24 months after PKP. In one patient without systemic therapy, a recurrence in corneal grafts occurred within 12 months of PKP. In eight patients without systemic therapy, PPK remained stable. In conclusion, systemic therapy for MM patients reduced corneal opacity in 30% of treated patients. Furthermore, systemic therapy performed before PKP in patients without conventional systemic therapy indication (MGOS) likely postpones PPK recurrence in the corneal graft. Full article
(This article belongs to the Special Issue Corneal Disease: Clinical Insights and Management Approaches)
►▼ Show Figures

Figure 1

Review

Jump to: Research

15 pages, 670 KiB  
Review
Therapeutic Targets in the Management of Dry Eye Disease Associated with Sjögren’s Syndrome: An Updated Review of Current Insights and Future Perspectives
by Abdulmohsen Almulhim
J. Clin. Med. 2024, 13(6), 1777; https://doi.org/10.3390/jcm13061777 - 20 Mar 2024
Viewed by 756
Abstract
Dry eye disease (DED) is a continuing medical challenge, further worsened in the autoimmune inflammatory hyperactivation milieu of Sjögren’s syndrome (SS) due to disturbances to innate and adaptive immunity with malfunctioning neuro-endocrine control. However, the pathogenetic mechanisms of SS DED are not fully [...] Read more.
Dry eye disease (DED) is a continuing medical challenge, further worsened in the autoimmune inflammatory hyperactivation milieu of Sjögren’s syndrome (SS) due to disturbances to innate and adaptive immunity with malfunctioning neuro-endocrine control. However, the pathogenetic mechanisms of SS DED are not fully established. This review summarized the available evidence, from systematic reviews, meta-analyses, and randomized clinical trials, for the efficacy and safety of the available ocular therapeutics for the management of SS DED. Relevant studies were obtained from major databases using appropriate keywords. The available largely empirical symptomatic, supportive, and restorative treatments have significant limitations as they do not alter local and systemic disease progression. Topical therapies have expanded to include biologics, surgical approaches, scleral lens fitting, the management of lid margin disease, systemic treatments, nutritional support, and the transplantation of stem cells. They are not curative, as they cannot permanently restore the ocular surface’s homeostasis. These approaches are efficacious in the short term in most studies, with more significant variability in outcome measures among studies in the long term. This review offers an interdisciplinary perspective that enriches our understanding of SS DED. This updated review addresses current knowledge gaps and identifies promising areas for future research to overcome this medical challenge. Full article
(This article belongs to the Special Issue Corneal Disease: Clinical Insights and Management Approaches)
►▼ Show Figures

Figure A1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop